News

|

Feeds

|

Email

DUBLIN, July 5, 2021 /PRNewswire/ -- The "Comprehensive Overview of FDA Regulatory Compliance for Drug and Biotech Products" conference has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This course is designed to provide participants with an up-to-date understanding of the drug and biotech requirements for FDA regulatory compliance, successful approaches to compliance, and strategies for meeting the concerns of regulators.

Attendees will leave with a comprehensive understanding of FDA drug regulations and be prepared for the upcoming changes to the International Council for Harmonization(ICH) Good Clinical Practice (GCP) E6 requirements in the US. The ICH E6(R3) Draft has been released for early consultation and the important changes are covered in this course.

Additional benefits of this FDA Regulatory Compliance class include:

    --  FDA inspectional authority and processes including 483s, Warning
        Letters, recalls, and other potential actions
    --  The role of clinical data in supporting product approval
    --  FDA Quality by Design initiatives
    --  Update on FDA electronic submission requirements
    --  The benefits of a quality management system beyond the manufacturing
        environment

Time: 11:00am - 5:00pm EDT

Who Should Attend:

This regulatory compliance course is designed to provide attendees with a strong foundation for understanding the drug and biotech regulatory requirements of the US FDA. The content is ideal for those looking for an introduction to regulatory compliance or who need a refresher on current compliance trends within the regulated environment.

Typical attendees include those in the following disciplines:

    --  Regulatory Affairs
    --  Manufacturing/Production
    --  Research and Development
    --  Quality Assurance & Control
    --  Development and preparation of submission material

This course is ideal for new hires, as well as Managers, Directors, and Vice Presidents of Regulatory Affairs and Quality Assurance. All levels of experience will benefit from this course.

Agenda:

First Day

1. Introduction

    --  FDA delegated authority and powers
    --  FDA compliance: regulations, guidelines, internal agency controls
    --  FDA enforcement
        --  483s
        --  Warning Letters
        --  Consent Decrees
        --  Seizure
        --  Recalls

2. Interpreting Regulations

    --  Review of applicable regulations
    --  FDC ACT
    --  CFR
        --  Establishing clear criteria
        --  Establishing clear SOPs and policies
        --  Managing the process

3. Audits and outsourcing

    --  Auditor qualifications
    --  Use of contract support
    --  Internal auditing procedures and schedule
        --  Key critical audit areas
        --  Audit expectations of site personnel
    --  Staff training

4. Management Oversight

    --  Quality Policy
    --  Management Review
        --  Escalation of issues to upper management
        --  Communication, decision making and transparency across management
    --  Resourcing

Second Day

5. Navigating FDA

    --  Website Review
    --  Investigator Operations Manual
    --  Compliance Policy Guides and Program Manuals

6. Emerging Trends at the FDA

    --  New compliance issues
    --  Drug shortage crisis
    --  Counterfeit drug issues and growing concerns
    --  Biosimilar approval pathways

7. Drug Development and Approval Process

    --  Drug Development
        --  QbD product development and design
        --  Risk analysis
        --  Post approval changes to process, methods etc.
    --  Regulatory Filings
        --  Key elements of IND, NDA/ANDA applications and FDA expectations
        --  Electronic CTD format and content, most submitted through ESG
            (Electronic Submissions Gateway)
    --  FDA Review and Approval Process
    --  Post Approval Submissions

8. Successful Approaches to Compliance

    --  Internal Auditing Procedure and Schedule
    --  Gap Analysis
        --  Regulations, Guidances and Procedures
    --  Remediation Plan
        --  CAPAs
        --  Change Control Process
        --  Assignment of resources to correct issues
    --  Training Procedure and Curriculums
    --  FDA communication
        --  Direct communication (emails, phone calls)
        --  Recalls
        --  Post approval submissions - annual reports, ADE reporting

9. Summary

    --  Key Issues
    --  Questions and resources

For more information about this conference visit https://www.researchandmarkets.com/r/wrn832

Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

View original content:https://www.prnewswire.com/news-releases/fda-regulatory-compliance-for-drug-and-biotech-products-overview-two-day-online-course-july-27-28-2021-301325452.html

SOURCE Research and Markets

Email

|

Slashdot

|

Digg

|

Del.icio.us

|

Feeds

RELATED NEWS ARTICLES

Asetek - Mandatory Notification of Trade | Jan 22, 2026 BC.GAME to Host "Stay Untamed" Night During Abu Dhabi's Packed Web3 Summit Week | Jan 22, 2026 Tomorrowland Brings the Magic to Shanghai for a Spectacular First Indoor Edition in China | Jan 22, 2026 Rent Manager Earned Best Real Estate Software Product Award and Multiple Review Badges from G2 Platform | Jan 22, 2026 Auburn University's Applied Research Institute Expands Advanced Manufacturing Capabilities with CF3D Enterprise Cell | Jan 22, 2026 California Divorce Mediation Center Unveils Modern Website Redesign | Jan 22, 2026 AMPERA ANNOUNCES LOCATION FOR GLOBAL HEADQUARTERS | Jan 22, 2026 Immutable Announces First Co-Founder-Hosted Live Webinar: How to Dominate Your Steam Launch | Jan 22, 2026 Gemmy Alerts Customers: Fake Websites Target Holiday Decorators | Jan 22, 2026 Culture and tourism sectors thrive in Xiamen | Jan 22, 2026